]Prevalence of carotid atherosclerosis in hypertension: Preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA)

A. Zanchetti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In the ELSA trial, the effects of lacidipine-based treatment and β-blocker (atenolol)-based treatment on the development and progression of carotid wall alterations are assessed in hypertensive patients. The primary endpoint of this study is the rate of change in the intima-media thickness of the carotid artery wall, measured with B-mode ultrasound. About 2300 hypertensive patients have been recruited and randomized to either of the antihypertensive agents. Baseline data for 1965 patients are available, showing a high prevalence of carotid wall lesions: about 82% of the subjects have an intima-media thickness ≤1.3 mm, defined as plaque in the ELSA protocol; 16% of the subjects have intima-media thickening (≤1.0 mm,

Original languageEnglish
Pages (from-to)30-35
Number of pages6
JournalBlood Pressure, Supplement
Volume5
Issue number4
Publication statusPublished - 1996

Fingerprint

Carotid Artery Diseases
Atherosclerosis
Hypertension
Atenolol
Carotid Arteries
Antihypertensive Agents
Therapeutics
lacidipine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

@article{3b304bb0f4d14da8ba59d88be05b792e,
title = "]Prevalence of carotid atherosclerosis in hypertension: Preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA)",
abstract = "In the ELSA trial, the effects of lacidipine-based treatment and β-blocker (atenolol)-based treatment on the development and progression of carotid wall alterations are assessed in hypertensive patients. The primary endpoint of this study is the rate of change in the intima-media thickness of the carotid artery wall, measured with B-mode ultrasound. About 2300 hypertensive patients have been recruited and randomized to either of the antihypertensive agents. Baseline data for 1965 patients are available, showing a high prevalence of carotid wall lesions: about 82{\%} of the subjects have an intima-media thickness ≤1.3 mm, defined as plaque in the ELSA protocol; 16{\%} of the subjects have intima-media thickening (≤1.0 mm,",
author = "A. Zanchetti",
year = "1996",
language = "English",
volume = "5",
pages = "30--35",
journal = "Blood Pressure, Supplement",
issn = "0803-8023",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - ]Prevalence of carotid atherosclerosis in hypertension

T2 - Preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA)

AU - Zanchetti, A.

PY - 1996

Y1 - 1996

N2 - In the ELSA trial, the effects of lacidipine-based treatment and β-blocker (atenolol)-based treatment on the development and progression of carotid wall alterations are assessed in hypertensive patients. The primary endpoint of this study is the rate of change in the intima-media thickness of the carotid artery wall, measured with B-mode ultrasound. About 2300 hypertensive patients have been recruited and randomized to either of the antihypertensive agents. Baseline data for 1965 patients are available, showing a high prevalence of carotid wall lesions: about 82% of the subjects have an intima-media thickness ≤1.3 mm, defined as plaque in the ELSA protocol; 16% of the subjects have intima-media thickening (≤1.0 mm,

AB - In the ELSA trial, the effects of lacidipine-based treatment and β-blocker (atenolol)-based treatment on the development and progression of carotid wall alterations are assessed in hypertensive patients. The primary endpoint of this study is the rate of change in the intima-media thickness of the carotid artery wall, measured with B-mode ultrasound. About 2300 hypertensive patients have been recruited and randomized to either of the antihypertensive agents. Baseline data for 1965 patients are available, showing a high prevalence of carotid wall lesions: about 82% of the subjects have an intima-media thickness ≤1.3 mm, defined as plaque in the ELSA protocol; 16% of the subjects have intima-media thickening (≤1.0 mm,

UR - http://www.scopus.com/inward/record.url?scp=0029987339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029987339&partnerID=8YFLogxK

M3 - Article

C2 - 8973780

AN - SCOPUS:0029987339

VL - 5

SP - 30

EP - 35

JO - Blood Pressure, Supplement

JF - Blood Pressure, Supplement

SN - 0803-8023

IS - 4

ER -